CN-122005643-A - Application of lonicera japonica and extract thereof in preparing medicine for treating glaucoma

Abstract

The application relates to the technical field of medicines, in particular to application of lonicera japonica and extracts thereof in preparing medicines for treating glaucoma. The application discovers the trabecular meshwork cell and trabecular meshwork fibrosis resisting effect of the lonicera japonica extract and the active ingredient thereof, and can be applied to the preparation of medicaments for resisting trabecular meshwork fibrosis and preventing and treating trabecular meshwork fibrosis related diseases such as glaucoma. In particular to application of the lonicera japonica extract, chlorogenic acid, isochlorogenic acid A, dipsacoside B and macranthoside B in preparing medicines for resisting trabecular meshwork cells and animal fibrosis, and also can be used for preparing medicines for inhibiting up-regulation of FN, alpha-SMA and COL-1 protein levels and medicines for inhibiting up-regulation of FN1, ACTA2, COL1A1 and COL4A1 transcription levels. Has good potential of patent medicine and wide development, transformation and clinical application value and prospect.

Inventors

• LIN YAN
• TU BO
• CHEN TAO
• TAN HEPING
• LIAO SHANGGAO
• WANG QIAN
• ZHENG QIANG
• ZHANG XU

Assignees

• 贵州医科大学

Dates

Publication Date

20260512

Application Date

20260127

Claims (10)

1. 1. Application of flos Lonicerae and its extract in preparing medicine for treating glaucoma is provided.
2. 2. The use according to claim 1, wherein the medicament for treating glaucoma is an anti-trabecular meshwork cell fibrosis medicament.
3. 3. The use according to claim 1, wherein the medicament for treating glaucoma is a medicament for treating iridocorneal endothelial syndrome.
4. 4. The use according to claim 1, wherein the lonicera japonica extract comprises lonicera japonica extract or a target compound thereof.
5. 5. The use according to claim 4, wherein the lonicera japonica extract or target compound thereof comprises at least one of an active ingredient of the lonicera japonica extract, a pharmaceutically acceptable salt, an ester, a solvate, a stereoisomer and a tautomer of the active ingredient.
6. 6. The use according to claim 5, wherein the active ingredient comprises at least one of organic acids and triterpenoid saponins.
7. 7. The use according to claim 6, wherein the active ingredient comprises at least one of chlorogenic acid, isochlorogenic acid A, dipsacoside B, and macranthoside B.
8. 8. The use according to claim 7, wherein the structural formulae of chlorogenic acid, isochlorogenic acid a, dipsacoside b and macranthoside b are shown in formula 1 to formula 4 in order: formula 1: formula 2: ; formula 3: ; formula 4: 。
9. 9. The use according to claim 1, wherein the lonicera japonica extract is an alcohol extract of lonicera japonica.
10. 10. The use according to claim 1, wherein the lonicera japonica extract is a lonicera japonica aqueous extract.

Description

Application of lonicera japonica and extract thereof in preparing medicine for treating glaucoma Technical Field The invention relates to the technical field of medicines, in particular to application of lonicera japonica and extracts thereof in preparing medicines for treating glaucoma. Background The trabecular meshwork is located between schlemm's canal and the anterior chamber angle, is the requisite route for aqueous humor to flow back to schlemm's canal, and is the most predominant passage for aqueous humor outflow, accounting for about 70% of aqueous humor circulation, and therefore, pathological changes in trabecular meshwork tissue can seriously affect the normal maintenance of intraocular pressure. It is reported in the literature that abnormal accumulation of extracellular matrix proteins (ECM), such as fibronectin and collagen, causes fibrosis and hardening of trabecular meshwork tissue, thereby increasing aqueous outflow resistance, causing pathological elevated intraocular pressure, and thus increasing the probability of glaucoma. However, because the pathological mechanism of fibrosis is complex and has not been completely ascertained, the current medicines capable of specifically treating the fibrosis diseases are few, so that the development of novel anti-fibrosis medicines has wide application prospect and important social significance. Disclosure of Invention In order to solve the problems, the invention provides application of a lonicera japonica extract, chlorogenic acid, isochlorogenic acid A, dipsacus root saponin B and lonicera macranthoides saponin B in preparation of medicines for resisting trabecular meshwork cell fibrosis, which comprises the following specific steps: Application of flos Lonicerae and its extract in preparing medicine for treating glaucoma is provided. Further, the glaucoma treatment drug is an anti-trabecular meshwork cell fibrosis drug. The anti-trabecular meshwork cell fibrosis comprises inhibiting up-regulation of fibronectin expression of cells and/or inhibiting up-regulation of transcription level of at least one gene of fibronectin genes, alpha-smooth muscle actin genes, type I collagen genes and type IV collagen genes of cells. Further, the medicine for treating glaucoma is a medicine for treating iris-cornea endothelial syndrome. Further, the flos lonicerae extract comprises flos lonicerae extract or target compound thereof. Further, the lonicera japonica extract or the target compound thereof comprises at least one of an active ingredient of the lonicera japonica extract, and pharmaceutically acceptable salts, esters, solvates, stereoisomers and tautomers of the active ingredient. Further, the active ingredient includes at least one of organic acids and triterpenoid saponins. Further, the active ingredient comprises at least one of chlorogenic acid, isochlorogenic acid A, dipsacoside B and macranthoside B. Further, structural formulas of chlorogenic acid, isochlorogenic acid A, dipsacoside B and macranthoside B are shown in formula 1-formula 4 in sequence: formula 1: formula 2: ; formula 3: ; formula 4: 。 Further, the flos Lonicerae extract is flos Lonicerae ethanol extract. Further, the flos Lonicerae extract is flos Lonicerae water extract. Compared with the prior art, the invention has the technical effects that: The application innovatively discovers the trabecular meshwork cell fibrosis resistance of the lonicera japonica extract and the active ingredient thereof, and can be applied to the preparation of medicaments for resisting trabecular meshwork cell fibrosis and preventing and treating trabecular meshwork cell fibrosis related diseases such as glaucoma. In particular to application of the lonicera japonica extract, chlorogenic acid, isochlorogenic acid A, dipsacoside B and macranthoside B in preparing medicines for resisting trabecular meshwork cell fibrosis, and also can be used for preparing medicines for inhibiting up-regulation of FN, alpha-SMA and COL-1 protein levels and medicines for inhibiting up-regulation of FN1, ACTA2, COL1A1 and COL4A1 transcription levels. Has good potential of patent medicine and wide development, transformation and clinical application value and prospect. Drawings FIG. 1 is a graph showing cytotoxicity results of the aqueous extract of flos Lonicerae (WELF) and the alcoholic extract of flos Lonicerae (EELF) obtained by using Human Trabecular Meshwork Cells (HTMC) as a model in example 1, wherein the effects of different concentrations of a and WELF on the viability of human trabecular meshwork cells, and the effects of different concentrations of b and EELF on the viability of human trabecular meshwork cells; FIG. 2 is a graph showing the effect of examples 2 WELF, EELF on the expression levels of the fibrosis markers FN, α -SMA in a TGF- β1 induced human trabecular meshwork cell fibrosis model, a is the result of SDS-PAGE electrophoresis, and b is a quantitative analysis statistical graph; FIG. 3 is a graph sho